Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $84.
Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $84.